BANGKOK, July 1 (TNA) – A research has found that a COVID-19 vaccine jointly developed by Mahidol University and the Government Pharmaceutical Organization (GPO) stimulated strong immunity.
The university through its Mahidol Channel reported that the HXP-GPOVac vaccine proved to stimulate strong immunity among volunteers during its first stage of human trials.
HXP-GPOVac is an inactivated vaccine. The Faculty of Tropical Medicine of Mahidol University and GPO developed it and started the first phase of human trials in March.
Local and foreign laboratory tests showed that the vaccine effectively stimulated immunity. An official report on the test results was expected within this month.
Researchers in the vaccine development team will later select the two best formulas out of five formulas for testing with 250 people in the second phase of human trials next month. Later the best formula will be picked up for the third stage of human trials. (TNA)
